[225Ac]-FPI-1966

N/A

Report date: 2025/09/12 15:57:47

Base Information

Drug Name[225Ac]-FPI-1966

Drug Alias Name[225Ac]-FPI-1966FPI-1966

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody diagnosticsRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Nuclides > Actinium > 225Ac +[4]

Mechanisms of ActionFibroblast growth factor receptor 3 antagonists

TargetsFibroblast growth factor receptor 3

Therapy Area/IndicationsSolid tumoursUrinary Bladder NeoplasmsLung Neoplasms +[9]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesAustralia

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesFusion Pharmaceuticals Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesFusion Pharmaceuticals Inc

Active IndicationsN/A

Inactive IndicationsSolid tumoursUrinary Bladder NeoplasmsLung Neoplasms +[9]

Other Information

ATC CodeN/A